{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:29:53Z","timestamp":1794810593847,"version":"4.9.1"},"reference-count":52,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Literature on the preferred anticoagulant for treating left ventricular thrombus (LVT) is lacking. Thus, our objective was to compare the efficacy of DOACs versus warfarin in treating LVT. Methods: Databases were searched for RCTs and adjusted observational studies that compared DOAC versus warfarin through March 2024. The primary efficacy outcomes of interest were LVT resolution, systemic embolism, composite of stroke, and TIA. The primary safety outcomes encompassed all-cause mortality and bleeding events. Results: Our meta-analysis including 31 studies demonstrated that DOAC use was associated with higher odds of thrombus resolution (OR: 1.08, 95% CI: 0.86\u20131.31, p: 0.46). A statistically significant reduction in the risk of stroke\/TIA was observed in the DOAC group versus the warfarin group (OR: 0.65, 95% CI: 0.48\u20130.89, p: 0.007). Furthermore, statistically significant reduced risks of all-cause mortality (OR: 0.68, 95% CI: 0.47\u20130.98, p: 0.04) and bleeding events (OR: 0.70, 95% CI: 0.55\u20130.89, p: 0.004) were observed with DOAC use as compared to warfarin use. Conclusion: Compared to VKAs, DOACs are noninferior as the anticoagulant of choice for LVT treatment. However, further studies are warranted to confirm these findings.<\/jats:p>","DOI":"10.3390\/ph17060708","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T10:06:01Z","timestamp":1717409161000},"page":"708","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Meta-Analysis of the Safety and Efficacy of Direct Oral Anticoagulants for the Treatment of Left Ventricular Thrombus"],"prefix":"10.3390","volume":"17","author":[{"given":"Mounica","family":"Vorla","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Carle Foundation Hospital, Urbana, IL 61822, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-4067","authenticated-orcid":false,"given":"Dinesh K.","family":"Kalra","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Louisville, Louisville, KY 40292, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamacardio.2018.1086","article-title":"Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment","volume":"3","author":"McCarthy","year":"2018","journal-title":"JAMA Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0002-8703(92)90757-M","article-title":"Ventricular Thrombi and Thromboembolism in Dilated Cardiomyopathy: A Prospective Follow-up Study","volume":"123","author":"Falk","year":"1992","journal-title":"Am. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/0002-9149(83)90588-X","article-title":"Frequency and Embolic Potential of Left Ventricular Thrombus in Dilated Cardiomyopathy: Assessment by 2-Dimensional Echocardiography","volume":"52","author":"Gottdiener","year":"1983","journal-title":"Am. J. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.21037\/atm-20-7839","article-title":"Management of Left Ventricular Thrombus: A Narrative Review","volume":"9","author":"Okajima","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ehjcvp\/pvaa066","article-title":"Left Ventricular Thrombosis: New Perspectives on an Old Problem","volume":"7","author":"Massussi","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0735-1097(85)80336-3","article-title":"Embolic Potential of Left Ventricular Thrombus after Myocardial Infarction: A Two-Dimensional Echocardiographic Study of 119 Patients","volume":"5","author":"Visser","year":"1985","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.jacc.2020.01.057","article-title":"Antithrombotic Therapy for Patients with Left Ventricular Mural Thrombus","volume":"75","author":"Lattuca","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","first-page":"e362","article-title":"2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"Kushner","year":"2013","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the Management of Acute Coronary Syndromes: Developed by the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association","volume":"146","author":"Levine","year":"2022","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The Nuts and Bolts of PROSPERO: An International Prospective Register of Systematic Reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"ref_14","unstructured":"(2024, March 31). Ottawa Hospital Research Institute. Available online: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2147\/OAEM.S384109","article-title":"Retrospective Analysis of Left Ventricular Thrombus Among Heart Failure Patients with Reduced Ejection Fraction at a Single Tertiary Care Hospital in Somalia","volume":"14","author":"Abdi","year":"2022","journal-title":"Open Access Emerg. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s43044-021-00164-7","article-title":"Rivaroxaban versus Warfarin for the Management of Left Ventricle Thrombus","volume":"73","author":"Albabtain","year":"2021","journal-title":"Egypt. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12959-020-00242-x","article-title":"Direct Oral Anticoagulant Use in Left Ventricular Thrombus","volume":"18","author":"Ali","year":"2020","journal-title":"Thrombosis J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11239-020-02371-6","article-title":"Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin for the Treatment of Left Ventricular Thrombus","volume":"52","author":"Bass","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/1074248420967644","article-title":"Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: A Retrospective, Multicenter Study and Meta-Analysis of Existing Data","volume":"26","author":"Cochran","year":"2021","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_21","first-page":"74","article-title":"Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists","volume":"13","author":"Daher","year":"2021","journal-title":"Arch. Cardiovasc. Dis. Suppl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"ehz747.0118","DOI":"10.1093\/eurheartj\/ehz747.0118","article-title":"459 Direct Oral Anticoagulants Are an Effective Therapy for Left Ventricular Thrombus Formation","volume":"40","author":"Gama","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.amjmed.2020.05.025","article-title":"Treatment of Left Ventricular Thrombus With Direct Oral Anticoagulants: A Retrospective Observational Study","volume":"133","author":"Guddeti","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40256-022-00533-w","article-title":"Safety and Effectiveness of Direct Oral Anticoagulants Versus Warfarin for Treating Left Ventricular Thrombus","volume":"22","author":"Herald","year":"2022","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/clc.23741","article-title":"The Prognostic Impact of Left Ventricular Thrombus Resolution after Acute Coronary Syndrome and Risk Modulation via Antithrombotic Treatment Strategies","volume":"44","author":"Hofer","year":"2021","journal-title":"Clin. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10760296231179683","DOI":"10.1177\/10760296231179683","article-title":"Clinical Profile, Treatment, and Prognosis of Left Ventricular Thrombus in Dilated Cardiomyopathy","volume":"29","author":"Huang","year":"2023","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/ehf2.12718","article-title":"Direct Oral Anticoagulants Compared to Vitamin K Antagonist for the Management of Left Ventricular Thrombus","volume":"7","author":"Iqbal","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/JCPC.JCPC_41_20","article-title":"Apixaban versus Warfarin in Patients with Left Ventricular Thrombus: A Pilot Prospective Randomized Outcome Blinded Study Investigating Size Reduction or Resolution of Left Ventricular Thrombus","volume":"9","author":"Isa","year":"2020","journal-title":"J. Clin. Prev. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/j.cjca.2018.07.194","article-title":"Treatment of Left Ventricular Thrombus Using Warfarin versus Direct Oral Anticoagulants Following Anterior Myocardial Infarction","volume":"34","author":"Jaidka","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/ehjcvp\/pvaa096","article-title":"The Use of Novel Oral Anticoagulants Compared to Vitamin K Antagonists (Warfarin) in Patients with Left Ventricular Thrombus after Acute Myocardial Infarction","volume":"7","author":"Jones","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/ehf2.14369","article-title":"Factors Influencing Left Ventricular Thrombus Resolution and Its Significance on Clinical Outcomes","volume":"10","author":"Kim","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1570161120666221003104821","article-title":"Efficacy and Safety of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus After Acute Anterior Myocardial Infarction in Patients Who Underwent Percutaneous Coronary Intervention","volume":"20","author":"Liang","year":"2022","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1007\/s11739-021-02788-8","article-title":"Direct Oral Anticoagulants versus Warfarin for the Treatment of Left Ventricular Thrombosis","volume":"16","author":"Mihm","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e002111","DOI":"10.1136\/bmjoq-2022-002111","article-title":"Improving the Management of Left Ventricular Thrombus in a Tertiary Cardiology Centre: A Quality Improvement Project","volume":"12","author":"Rahunathan","year":"2023","journal-title":"BMJ Open Qual."},{"key":"ref_35","first-page":"45","article-title":"Left Ventricular Thrombus after ST Segment Elevation Myocardial Infarction: A Single-Centre Observational Study","volume":"133","author":"Ratnayake","year":"2020","journal-title":"N. Z. Med. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","article-title":"Off-Label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi","volume":"5","author":"Robinson","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amjcard.2023.01.018","article-title":"Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Treatment of Left Ventricular Thrombi\u2014Insights from a Swiss Multicenter Registry","volume":"194","author":"Seiler","year":"2023","journal-title":"Am. J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.11604\/pamj.2021.39.212.28585","article-title":"Treatment and Outcomes in Patients with Left Ventricular Thrombus\u2014Experiences from the Aga Khan University Hospital, Nairobi-Kenya","volume":"39","author":"Varwani","year":"2021","journal-title":"Pan Afr. Med. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/1060028020975111","article-title":"Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus","volume":"55","author":"Willeford","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.21037\/apm-21-1683","article-title":"Direct Oral Anticoagulants versus Vitamin K Antagonists for Patients with Left Ventricular Thrombus","volume":"10","author":"Xu","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00380-021-01921-z","article-title":"Rivaroxaban versus Vitamin K Antagonists (Warfarin) Based on the Triple Therapy for Left Ventricular Thrombus after ST-Elevation Myocardial Infarction","volume":"37","author":"Zhang","year":"2022","journal-title":"Heart Vessel."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1008031","DOI":"10.3389\/fphar.2022.1008031","article-title":"Rivaroxaban in Heart Failure Patients with Left Ventricular Thrombus: A Retrospective Study","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_43","unstructured":"Cochrane RevMan (2024, January 13). RevMan: Systematic Review and Meta-Analysis Tool for Researchers Worldwide. Available online: https:\/\/revman.cochrane.org\/info."},{"key":"ref_44","unstructured":"ScienceDirect Topics (2024, March 31). Mantel Haenszel Test\u2014An Overview. Available online: https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/mantel-haenszel-test."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2021.01.049","article-title":"Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT Trial)","volume":"77","author":"Abdelnabi","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ehjcvp\/pvab057","article-title":"Apixaban vs. Warfarin in Patients with Left Ventricular Thrombus: A Prospective Multicentre Randomized Clinical Trial","volume":"8","author":"Alcalai","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cjco.2022.12.003","article-title":"Apixaban in Patients With Post-Myocardial Infarction Left Ventricular Thrombus: A Randomized Clinical Trial","volume":"5","author":"Youssef","year":"2023","journal-title":"CJC Open"},{"key":"ref_48","unstructured":"(2024, April 15). Use of XARELTO in Ventricular Thrombus. Available online: https:\/\/www.janssenscience.com\/products\/xarelto\/medical-content\/use-of-xarelto-in-ventricular-thrombus."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1476-7120-4-20","article-title":"Incidence of Post Myocardial Infarction Left Ventricular Thrombus Formation in the Era of Primary Percutaneous Intervention and Glycoprotein IIb\/IIIa Inhibitors. A Prospective Observational Study","volume":"4","author":"Rehan","year":"2006","journal-title":"Cardiovasc. Ultrasound"},{"key":"ref_50","first-page":"100395","article-title":"Incidence and Predictors of Left Ventricular Thrombus Formation Following Acute ST-Segment Elevation Myocardial Infarction: A Serial Cardiac MRI Study","volume":"24","author":"Phan","year":"2019","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.amjcard.2013.12.015","article-title":"Incidence and Predictors of Early Left Ventricular Thrombus after ST-Elevation Myocardial Infarction in the Contemporary Era of Primary Percutaneous Coronary Intervention","volume":"113","author":"Gianstefani","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12944-015-0054-x","article-title":"Lipid Lowering Efficacy and Safety of Ezetimibe Combined with Rosuvastatin Compared with Titrating Rosuvastatin Monotherapy in HIV-Positive Patients","volume":"14","author":"Saeedi","year":"2015","journal-title":"Lipids Health Dis."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/6\/708\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:50:50Z","timestamp":1760107850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/6\/708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ph17060708"],"URL":"https:\/\/doi.org\/10.3390\/ph17060708","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}